Divided opinion
Amgen v Sanofi: narrowing the scope of protection for antibody inventions?
MAGAZINE EXCLUSIVE
PharmaTimes Magazine
PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.
PharmaTimes print and digital versions have a total circulation of 23,184, reaching right across the industry into every company and every function. What's more, our circulation includes 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.
Click to subscribe to PharmaTimes in paper or print, or to sign up for our industry-leading daily and weekly news elerts.
You can read the latest issue as well as our extensive archive below or get in touch with the editorial or sales team.
Magazine highlights
View more from the latest edition
Supply chain security
Is blockchain the answer to protecting against counterfeits and medicines shortages?
MAGAZINE EXCLUSIVE
A view from the top
What’s next for account management?
SMART PEOPLE: Jenny Ousbey
OVID Health founder Jenny Ousbey discusses the pandemic, patient advocacy and the Patient Partnership Index
Patient Files: HIV
Samantha Dawson details her experiences living with HIV
HIV: the fight continues
Gilead Sciences’ global patient engagement lead and former HIV nurse specialist Geraldine Reilly explores today’s fight against the virus – as TV series It’s A Sin brings back memories of working on the frontline during the AIDS epidemic of the 1980s and 1990s
Smart People: Dr Nick West
Abbott’s Dr Nick West talks to PharmaTimes about going beyond intervention to improve the care of cardiovascular patients in the UK
The first fallout
Taking a look at the recent dispute between the EU Commission and AstraZeneca over the ins and outs of its contract, Stuart Evans, commercial litigation expert and partner at law firm BLM, examines what this could represent for EU/UK cross-border pharma relations
